A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer

Sponsor

CASI Pharmaceuticals, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT00607607

Collaborator

(none)

Enrollment

Locations

Arms

Duration (Months)

7.3

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Patients will be treated with MKC-1, twice daily for 14 consecutive days every four weeks (a cycle of MKC-1 chemotherapy), until disease progression or unacceptable toxicities. Patients will be stratified to Arm A (ovarian cancer) or Arm B (endometrial cancer), and will receive identical treatment regimens.

Condition or Disease	Intervention/Treatment	Phase
Ovarian Cancer Endometrial Cancer	Drug: MKC-1	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

44 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Recurrent or Resistant Epithelial Ovarian Cancer or Advanced Endometrial Cancer

Study Start Date :

Jan 1, 2008

Actual Primary Completion Date :

Jun 1, 2011

Actual Study Completion Date :

Jan 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: A Ovarian Cancer Patients	Drug: MKC-1 capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
Experimental: B Endometrial Cancer Patients	Drug: MKC-1 capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles

Arm

Intervention/Treatment

Experimental: A

Ovarian Cancer Patients

Drug: MKC-1

capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles

Experimental: B

Endometrial Cancer Patients

Drug: MKC-1

capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles

Outcome Measures

Primary Outcome Measures

Tumor response rate (based on tumor measurements according to the RECIST criteria) or CA-125 [Every 4 to 8 weeks]

Secondary Outcome Measures

Time to progression [Time of progression]
Adverse events spontaneously declared by the patients or noted during physical examination and laboratory tests. [As reported]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Provide written informed consent (and HIPAA authorization for release of protected health information, as applicable) prior to any study related assessments.
Histologically confirmed epithelial ovarian cancer, primary peritoneal carcinomatosis, fallopian tube cancers, or endometrial cancer.
Age > 18 years at the time of consent.
Arm A: Ovarian Cancer Patients:

Must have failed at least one prior platinum based and one taxane based chemotherapeutic regimen. [Platinum failure is defined as platinum-refractory (progression while receiving a platinum-containing regimen) or platinum-resistant (disease progression within 6 months from completion of platinum containing regimen)].
Have measurable disease according to RECIST or CA 125 criteria according to GCIG (CA-125 value of > 2 xULN).
Have no more than 3 prior regimens for their disease.

Arm B: Endometrial Cancer Patients:

Have no more than 3 prior regimens for their disease
Have measurable disease according to RECIST.

ECOG performance status of 0, 1, or 2.
The following laboratory results, within 10 days of MKC-1 administration:

Hemoglobin greater than or equal to 90 g/L (9 g/dL)
Absolute neutrophil count greater than or equal to 1.5 x 109/L
Platelet count greater than or equal to 100 x 109/L
Serum creatinine less than or equal to 1.5 x ULN (upper limit of normal)
AST less than or equal to 2.5 x ULN
Serum Albumin greater than or equal to 30 g/L (3.0 g/dL)
Total bilirubin less than or equal to ULN

Exclusion Criteria:

Administration of cancer specific therapy within the following periods prior to study drug initiation:

chemotherapy less than 3 weeks prior;
hormonal therapy less than one week prior;
radiation therapy less than 2 weeks prior.

Requirement for paracentesis > 2 liters/week.
Pregnant or breast-feeding women. Female patients must be postmenopausal, surgically sterile, or they must agree to use a physical method of contraception. Female patient with childbearing potential must have a negative pregnancy test within 10 days before the first MKC-1 administration.
Known CNS metastases unless treated, clinically stable, and not requiring steroids.
Clinical evidence of significant bowel obstruction, active uncontrolled malabsorption syndromes, or a history of total gastrectomy.
Uncontrolled hypercalcemia (serum calcium-corrected > 3 mmol/L [12 mg/dL]).
Serious cardiac condition (Class III/IV congestive heart failure according to New York Heart Association classification); documented acute myocardial infarction within the previous 6 months.
Any medical conditions that, in the investigator's opinion, would impose excessive risk to the patient. These include: infection requiring parenteral or oral anti-infective treatment, any altered mental status, or any psychiatric condition that would interfere with the understanding of the informed consent.
Patients with previous malignancies unless free of recurrence for at least 5 years except cured basal cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix.
Treatment with antiretroviral therapy metabolized through CYP3A4 (including indinavir, nelfinavir, ritonavir and saquinavir).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Juravinski Cancer Centre	Hamilton	Ontario	Canada	L8V 5C2
2	Cancer Centre of Southeastern Ontario at Kingston General Hospital	Kingston	Ontario	Canada	K7L 5P9
3	London Health Sciences Centre	London	Ontario	Canada	N6A 4L6
4	Credit Valley Hospital	Mississauga	Ontario	Canada	L5M 2N1
5	Princess Margaret Hospital	Toronto	Ontario	Canada	M5G 2M9
6	Hopital Notre-Dame du CHUM	Montreal	Quebec	Canada	H2L 4M1